加齢黄斑変性症（AMD）治療薬市場 – 2029年までの世界予測

Report Overview

The Age-Related Macular Degeneration (AMD) Drugs market is projected to reach USD 17.37 Billion from 2029 USD 10.46 Billion in 2024 growing at a CAGR of 10.7% during the forecast period of 2024-2029.

加齢黄斑変性症（AMD）治療薬市場は、2029年の104億6000万米ドルから2024年には173億7000万米ドルに達すると予測されており、2024年から2029年の予測期間中に10.7％のCAGRで成長します。

Major pharmaceutical companies have reported a 2 fold increase in the geriatric population (above 60 years of age) by 2050, and this increase will have an impact on the number of AMD cases as AMD is associated with old age. Lifestyle factors such as smoking, diet, and physical activity also significantly influence AMD risk. For instance, studies have shown that smoking can accelerate the onset of AMD by an average of 5.5 years. According to the Macular Society (UK), smokers are likely to develop AMD up to 10 years earlier than non-smokers. Leading ophthalmologists from the UAE and UK have reported a decrease in the onset age of AMD and concluded that unhealthy lifestyle habits can bring down this age further by the next decade. Researchers from Japan conducted research to examine the effects of alcohol on AMD and concluded that moderate to heavy alcohol consumption increases the risk of early AMD. Similarly, a higher body mass index (BMI) is associated with an increased risk of both early and late AMD, as obesity and lack of physical activity are linked to increased oxidative stress and inflammation, contributing to AMD development. Rising incidences of AMD are driving companies to expand their drug pipeline and seek fast-track designations to advance their products’ availability. For instance, in 2021 Opthea Limited received fast-track designation for its pipeline drug OPT-302 developed for the treatment of patients with wet AMD, advancing its development process. Similarly in 2023, Adverum Biotechnology received an Innovation Passport from the UK’s MHRA for its pipeline drug Ixo-vec (ixoberogene soroparvovec), helping to speed up patient access and regulatory support in the UK. These developments along with a rising number of AMD cases are projected to increase the demand for AMD drugs in the market.

“Vabysmo drug is set to register the highest growth during 2024-2029 in the Age-Related Macular degeneration (AMD) drugs market”

Based on products the Age-Related Macular Degeneration (AMD) drugs market is segmented into Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and other products including Beovu, Conbercept, Byooviz, and Izervay among others. Vabysmo (faricimab-svoa) is set to register the highest growth rate during the forecast period of 2024-2029, owing to the positive feedback received from patients and ophthalmologists for the treatment of AMD. The rising adoption of the drug is also supported by the 4x increase in the revenue of the drug from 2022 to 2023. Studies conducted to test the efficacy and tolerability of the drug have concluded that the drug is well tolerated in people with retinal disorders and can preserve vision while reducing the frequency of injections elevating the treatment burden of the patients. The drug is also used for the treatment of patients who showed resistance to the treatment from Eylea (aflibercept) and has significant improvement in visual acuity.

“Hospitals to witness the high growth in the AMD drugs market by End User”

Based on end users, the age-related macular degeneration (AMD) drugs market is segmented into hospitals, specialty centers, and long-term care facilities. Hospitals are projected to witness the highest growth rate during the forecast period of 2024-2029. This growth can be attributed to factors such as the ability of hospitals to provide comprehensive care to patients through advanced healthcare infrastructure and specialized treatment facilities. Additionally, hospitals are more abundant than any other end user (Specialty centers and Long-term care facilities) and modern hospitals are generally multispeciality in nature offering specialized treatment. Hospitals often collaborate with long-term care (LTC) facilities to provide support such as ophthalmologists for the treatment of individuals living in the care facility. Moreover, hospitals also partner with pharmaceutical companies to ensure an optimal supply of AMD drugs for the patients.

“Biologics segment accounted for the highest growth rate in the Age-Related Macular Degeneration (AMD) drugs market by approval type”

Based on approval type, the age-related macular degeneration (AMD) drugs market is segmented into biologics and biosimilars. During the forecast period of 2024-2029, biologics are projected to register the highest growth in the AMD drugs market by approval type. This high growth can be attributed to the increase in the number of approvals for biologics such as Vabysmo, Eylea HD, Syfovre, and Izervay, among others, for the treatment of AMD. Moreover, as these drugs are recently approved they are protected by patents and generally prevent biosimilar entry into the market. Additionally, improved reimbursement policies and comprehensive insurance coverage offered for biologics generally deter patients and ophthalmologists from choosing biosimilars over biologics. New innovative companies are also developing novel biologics for treating various forms of AMD supporting the growth of this segment.

“North America: The fastest-growing country in the Age-Related Macular Degeneration (AMD) drugs market”

The Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to register the highest CAGR during the forecast period. Factors such as rising AMD cases due to an increase in the geriatric population and accompanied by unhealthy lifestyle and dietary habits, and increasing pharmaceutical R&D spending, by major pharmaceutical and biotechnology companies present in the region, to develop novel therapies and drug delivery systems for AMD disease are driving the growth of AMD drugs in the region. Additionally, growing public-private partnerships, increasing government support and improved reimbursement policies further support the growth of the AMD drugs market in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side -70% and Demand Side – 30%
• By Designation: Managers -45%, CXOs and Directors -30%, and Executives – 25%
• By Region: North America-35%, Europe -25%, Asia-Pacific -15%, Latin America-10%, Middle East-10% and Africa-5%

Lists of Companies Profiled in the Report:

• Regeneron Pharmaceuticals Inc. (US)
• Bayer AG (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Apellis Pharmaceuticals (US)
• Coherus BioSciences (US)
• Astellas Pharma Inc. (Japan)
• Biogen (US)
• STADA Arzneimittel AG (Germany)
• Formycon AG (Germany)
• Biocon. (India)
• Outlook Therapeutics, Inc. (US)
• Intas Pharmaceuticals Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Chengdu Kanghong Biotech Company (China)
• Sandoz Group AG (Switzerland)
• Stealth BioTherapeutics Inc. (US)
• Ocular Therapeutix, Inc. (US)
• Opthea Limited (Australia)
• Kodiak Sciences Inc. (US)
• Innovent Biologics, Inc. (China)
• Bio-Thera Solution (China)
• Alvotech (Iceland)
• Alteogen Inc. (South Korea)
• Shanghai Henlius Biotech, Inc. (China)
• Amgen Inc. (US)
• Ocumension Therapeutics. (China)
• Adverum Biotechnologies, Inc. (US)

Research Coverage:

This report provides a detailed picture of the age-related macular degeneration (AMD) drugs market. It aims at estimating the size and future growth potential of the market across different segments, such as products, molecules, type of AMD, approval type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Analysis of key drivers (Increasing risk of AMD due to changing lifestyle and dietary habits, Steady development and approvals of drugs and Favorable reimbursement and insurance policies), restraints (Off-Label Use of Drugs), opportunities (Shifting Focus on New Drug Modalities, Rapidly expanding market in developing countries, Need to address dry age-macular degeneration and geographic atrophy), and challenges (Non-adherence to treatments) influencing the growth of the Age-Related Macular Degeneration (AMD) durgs market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new therapy launches in the Age-Related Macular Degeneration (AMD) drugs market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various opportunities and developments across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Age-Related Macular Degeneration (AMD) drugs market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Novartis AG (Switzerland) among others in the Age-Related Macular Degeneration (AMD) drugs market.

Table of Contents

1            INTRODUCTION            32

1.1         STUDY OBJECTIVES      32

1.2         MARKET DEFINITION   33

1.3         INCLUSIONS AND EXCLUSIONS 33

1.4         STUDY SCOPE  34

1.4.1      MARKETS COVERED     34

1.4.2      YEARS CONSIDERED     35

1.4.3      CURRENCY CONSIDERED          35

1.5         STAKEHOLDERS            35

1.6         IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET            36

2            RESEARCH METHODOLOGY     37

2.1         RESEARCH DATA           37

2.1.1      SECONDARY DATA       38

2.1.2      PRIMARY DATA 38

2.2         MARKET SIZE ESTIMATION       40

2.2.1      BOTTOM-UP APPROACH           43

2.3         MARKET GROWTH FORECAST  44

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    46

2.5         RESEARCH ASSUMPTIONS         46

2.6         RESEARCH LIMITATIONS           47

2.7         RISK ANALYSIS 47

3            EXECUTIVE SUMMARY 48

4            PREMIUM INSIGHTS      53

4.1         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW        53

4.2         NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023        54

4.3         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF

AMD, 2024 VS. 2029 (USD MILLION)        54

4.4         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023 55

4.5         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

GEOGRAPHIC GROWTH OPPORTUNITIES         55

5            MARKET OVERVIEW     56

5.1         INTRODUCTION            56

5.2         MARKET DYNAMICS     56

5.2.1      DRIVERS            57

5.2.1.1   Changing lifestyle and dietary habits              57

5.2.1.2   Steady development and approvals of drugs   58

5.2.1.3   Favorable reimbursement and insurance policies         59

5.2.2      RESTRAINTS     60

5.2.2.1   Off-label use of drugs         60

5.2.3      OPPORTUNITIES           60

5.2.3.1   Shifting focus on new drug modalities            60

5.2.3.2   Rapidly expanding market in developing countries       61

5.2.3.3   Need to address dry age-related macular degeneration and geographic atrophy              62

5.2.4      CHALLENGES   63

5.2.4.1   Non-adherence to treatments          63

5.3         TECHNOLOGY ANALYSIS           64

5.3.1      KEY TECHNOLOGIES    64

5.3.1.1   Hybridoma technology      64

5.3.1.2   Recombinant DNA technology        64

5.3.1.3   Antibody engineering        65

5.3.2      ADJACENT TECHNOLOGIES      65

5.3.2.1   Tissue engineering (scaffold technology)       65

5.3.2.2   Artificial intelligence          66

5.3.2.3   Optogenetic technology     66

5.4         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67

5.5         PRICING ANALYSIS        67

5.5.1      AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE)       68

5.5.2      AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION     68

5.5.3      AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER            69

5.6         VALUE CHAIN ANALYSIS            70

5.7         SUPPLY CHAIN ANALYSIS          72

5.8         ECOSYSTEM ANALYSIS 73

5.9         PATENT ANALYSIS        75

5.10       REGULATORY ANALYSIS            77

5.10.1    REGULATORY LANDSCAPE       77

5.10.1.1 US         78

5.10.1.2 Europe  79

5.10.1.3 Emerging economies         79

5.10.2    REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 80

5.11       PORTER’S FIVE FORCES ANALYSIS         83

5.11.1    INTENSITY OF COMPETITIVE RIVALRY 84

5.11.2    BARGAINING POWER OF SUPPLIERS     85

5.11.3    BARGAINING POWER OF BUYERS           85

5.11.4    THREAT OF SUBSTITUTES         85

5.11.5    THREAT OF NEW ENTRANTS    85

5.12       KEY CONFERENCES AND EVENTS, 2024–2025     86

5.13       KEY STAKEHOLDERS AND BUYING CRITERIA    87

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         87

5.13.2    BUYING CRITERIA         87

5.14       INVESTMENT/FUNDING ACTIVITY        89

5.15       PIPELINE ANALYSIS      89

5.16       CASE STUDY ANALYSIS 92

5.16.1    IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED

MACULAR DEGENERATION TREATMENT          92

5.16.2    ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED

MACULAR DEGENERATION TREATMENT          92

5.16.3    HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR

AGE-RELATED MACULAR DEGENERATION TREATMENT           92

5.17       IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET            93

6            AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT    95

6.1         INTRODUCTION            96

6.2         EYLEA & EYLEA HD       96

6.2.1      HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS

TO SPEED UP GROWTH             96

6.3         LUCENTIS         100

6.3.1      PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL

THICKNESS TO FAVOR GROWTH           100

6.4         VABYSMO          104

6.4.1      FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES

TO SUSTAIN GROWTH 104

6.5         SYFOVRE           107

6.5.1      INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED

MACULAR DEGENERATION TO BOOST MARKET            107

6.6         OTHER PRODUCTS       111

7            AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE 114

7.1         INTRODUCTION            115

7.2         AFLIBERCEPT   115

7.2.1      HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS

TO EXPEDITE GROWTH             115

7.3         FARICIMAB       119

7.3.1      FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH

STUDIES TO AUGMENT GROWTH         119

7.4         RANIBIZUMAB  122

7.4.1      ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET            122

7.5         PEGCETACOPLAN         126

7.5.1      HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO

CONTRIBUTE TO GROWTH      126

7.6         OTHER MOLECULES     129

8            AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE      133

8.1         INTRODUCTION            134

8.2         BIOLOGICS       134

8.2.1      HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES

TO SUPPORT GROWTH 134

8.3         BIOSIMILARS    138

8.3.1      LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH              138

9            AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD           142

9.1         INTRODUCTION            143

9.2         WET AMD          143

9.2.1      GROWING GERIATRIC POPULATION TO FACILITATE GROWTH              143

9.3         DRY AMD          147

9.3.1      INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH          147

10          AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER    151

10.1       INTRODUCTION            152

10.2       HOSPITALS       152

10.2.1    GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH       152

10.3       LONG-TERM CARE FACILITIES 156

10.3.1    NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET        156

10.4       SPECIALTY CENTERS    159

10.4.1    RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH       159

11          AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION             163

11.1       INTRODUCTION            164

11.2       NORTH AMERICA          164

11.2.1    MACROECONOMIC OUTLOOK FOR NORTH AMERICA   168

11.2.2    US         169

11.2.2.1 Rising investment in healthcare research & development

to propel market  169

11.2.3    CANADA            172

11.2.3.1 Favorable government initiatives to aid market growth 172

11.3       EUROPE             174

11.3.1    MACROECONOMIC OUTLOOK FOR EUROPE     176

11.3.2    GERMANY         178

11.3.2.1 Rising focus on clinical research with public-private partnerships to augment growth   178

11.3.3    UK         181

11.3.3.1 Ongoing technological advancements to promote growth           181

11.3.4    FRANCE             183

11.3.4.1 Growing investments in funding healthcare and allied technology to foster growth              183

11.3.5    ITALY   186

11.3.5.1 Comprehensive treatment coverage and funding for new therapies to fuel market              186

11.3.6    SPAIN   189

11.3.6.1 Growing number of collaborative projects to favor market growth            189

11.3.7    NETHERLANDS 192

11.3.7.1 Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market   192

11.3.8    REST OF EUROPE           194

11.4       ASIA PACIFIC    197

11.4.1    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC          200

11.4.2    CHINA  201

11.4.2.1 Strategic drug approvals to support market growth      201

11.4.3    JAPAN  204

11.4.3.1 Advanced healthcare infrastructure to encourage growth           204

11.4.4    INDIA   206

11.4.4.1 Regulatory reforms and aging population to boost market          206

11.4.5    AUSTRALIA       209

11.4.5.1 Increasing disease incidence and evolving treatment options to facilitate growth              209

11.4.6    SOUTH KOREA 212

11.4.6.1 Supportive regulatory environment to boost market     212

11.4.7    REST OF ASIA PACIFIC  214

11.5       LATIN AMERICA             216

11.5.1    MACROECONOMIC OUTLOOK FOR LATIN AMERICA     219

11.5.2    BRAZIL 220

11.5.2.1 Increasing rate of visual impairment to sustain growth 220

11.5.3    MEXICO             223

11.5.3.1 Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth  223

11.5.4    REST OF LATIN AMERICA          225

11.6       MIDDLE EAST  227

11.6.1    MACROECONOMIC OUTLOOK FOR MIDDLE EAST         230

11.6.2    GCC COUNTRIES           231

11.6.2.1 Saudi Arabia        233

11.6.2.1.1            Sustained health coverage and biosimilar drug approvals to propel market              233

11.6.2.2 UAE      235

11.6.2.2.1            Increasing focus on technological advancements, ongoing research, and government initiatives to support growth       235

11.6.2.3 Other GCC Countries        238

11.6.3    REST OF MIDDLE EAST 240

11.7       AFRICA 243

11.7.1    GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET      243

11.7.2    MACROECONOMIC OUTLOOK FOR AFRICA       245

12          COMPETITIVE LANDSCAPE       247

12.1       OVERVIEW        247

12.2       KEY PLAYER STRATEGY/RIGHT TO WIN             247

12.2.1    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET     248

12.3       REVENUE ANALYSIS, 2021–2023 250

12.4       MARKET SHARE ANALYSIS, 2023             251

12.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   253

12.5.1    STARS  254

12.5.2    EMERGING LEADERS    254

12.5.3    PERVASIVE PLAYERS     254

12.5.4    PARTICIPANTS 254

12.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      256

12.5.5.1 Company footprint            256

12.5.5.2 Molecule footprint             257

12.5.5.3 Approval footprint             258

12.5.5.4 Type of AMD footprint      259

12.5.5.5 Region footprint  260

12.6       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          261

12.6.1    PROGRESSIVE COMPANIES       261

12.6.2    RESPONSIVE COMPANIES          261

12.6.3    DYNAMIC COMPANIES 261

12.6.4    STARTING BLOCKS       261

12.6.5    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023             263

12.7       COMPANY VALUATION AND FINANCIAL METRICS        265

12.7.1    COMPANY VALUATION 265

12.7.2    FINANCIAL METRICS    266

12.8       BRAND/PRODUCT COMPARISON          267

12.9       COMPETITIVE SCENARIO          268

12.9.1    PRODUCT LAUNCHES & APPROVALS    268

12.9.2    DEALS  270

12.9.3    EXPANSIONS    271

13          COMPANY PROFILES    272

13.1       KEY PLAYERS   272

13.1.1    F. HOFFMANN-LA ROCHE LTD 272

13.1.1.1 Business overview 272

13.1.1.2 Products offered  273

13.1.1.3 Recent developments         274

13.1.1.3.1            Product launches & approvals          274

13.1.1.4 MnM view           275

13.1.1.4.1            Right to win         275

13.1.1.4.2            Strategic choices  275

13.1.1.4.3            Weaknesses and competitive threats 275

13.1.2    REGENERON PHARMACEUTICALS INC. 276

13.1.2.1 Business overview 276

13.1.2.2 Products offered  277

13.1.2.3 Recent developments         277

13.1.2.3.1            Product launches & approvals          277

13.1.2.4 MnM view           277

13.1.2.4.1            Right to win         277

13.1.2.4.2            Strategic choices  278

13.1.2.4.3            Weaknesses and competitive threats 278

13.1.3    NOVARTIS AG   279

13.1.3.1 Business overview 279

13.1.3.2 Products offered  281

13.1.3.3 Recent developments         281

13.1.3.3.1            Product launches & approvals          281

13.1.3.3.2            Deals     282

13.1.3.4 MnM view           282

13.1.3.4.1            Right to win         282

13.1.3.4.2            Strategic choices  282

13.1.3.4.3            Weaknesses and competitive threats 282

13.1.4    BAYER AG          283

13.1.4.1 Business overview 283

13.1.4.2 Products offered  284

13.1.4.3 Recent developments         285

13.1.4.3.1            Product launches & approvals          285

13.1.4.4 MnM view           285

13.1.4.4.1            Right to win         285

13.1.4.4.2            Strategic choices  285

13.1.4.4.3            Weaknesses and competitive threats 286

13.1.5    APELLIS PHARMACEUTICALS   287

13.1.5.1 Business overview 287

13.1.5.2 Products offered  287

13.1.5.3 Recent developments         288

13.1.5.3.1            Product launches & approvals          288

13.1.5.3.2            Deals     288

13.1.5.4 MnM view           289

13.1.5.4.1            Right to win         289

13.1.5.4.2            Strategic choices  289

13.1.5.4.2.1         Weaknesses and competitive threats 289

13.1.6    ASTELLAS PHARMA INC.            290

13.1.6.1 Business overview 290

13.1.6.2 Products offered  291

13.1.6.3 Recent developments         292

13.1.6.3.1            Product launches & approvals          292

13.1.6.3.2            Deals     292

13.1.7    STADA ARZNEIMITTEL AG        293

13.1.7.1 Business overview 293

13.1.7.2 Products offered  294

13.1.7.3 Recent developments         295

13.1.7.3.1            Product launches & approvals          295

13.1.7.3.2            Deals     296

13.1.8    BIOGEN             297

13.1.8.1 Business overview 297

13.1.8.2 Products offered  298

13.1.8.3 Recent developments         299

13.1.8.3.1            Product launches & approvals          299

13.1.9    FORMYCON AG 301

13.1.9.1 Business overview 301

13.1.9.2 Products offered  302

13.1.9.3 Recent developments         303

13.1.9.3.1            Product launches & approvals          303

13.1.9.3.2            Deals     304

13.1.10  COHERUS BIOSCIENCES             305

13.1.10.1             Business overview 305

13.1.10.2             Products offered  305

13.1.10.3             Recent developments         306

13.1.10.3.1          Products launches & approvals        306

13.1.10.3.2          Other developments          306

13.1.11  BIOCON             307

13.1.11.1             Business overview 307

13.1.11.2             Product offered   308

13.1.11.3             Recent developments         309

13.1.11.3.1          Product launches & approvals          309

13.1.11.3.2          Deals     309

13.1.12  OUTLOOK THERAPEUTICS, INC.            310

13.1.12.1             Business overview 310

13.1.12.2             Products offered  310

13.1.12.3             Recent developments         311

13.1.12.3.1          Product launches & approvals          311

13.1.12.3.2          Deals     311

13.1.13  TEVA PHARMACEUTICAL INDUSTRIES LTD.     312

13.1.13.1             Business overview 312

13.1.13.2             Products offered  313

13.1.13.3             Recent developments         314

13.1.13.3.1          Product launches & approvals          314

13.1.13.3.2          Deals     314

13.1.14  INTAS PHARMACEUTICALS LTD.           315

13.1.14.1             Business overview 315

13.1.14.2             Products offered  315

13.1.15  SANDOZ GROUP AG      316

13.1.15.1             Business overview 316

13.1.15.2             Products offered  317

13.1.15.3             Recent developments         318

13.1.15.3.1          Product launches & approvals          318

13.1.15.3.2          Deals     318

13.1.15.3.3          Expansions          318

13.1.16  CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.  319

13.1.16.1             Business overview 319

13.1.16.2             Products offered  319

13.2       OTHER PLAYERS           320

13.2.1    OCULAR THERAPEUTIX, INC.    320

13.2.2    OPTHEA LIMITED         321

13.2.3    KODIAK SCIENCES INC. 322

13.2.4    BIO-THERA       323

13.2.5    AMGEN INC.      323

13.2.6    ALVOTECH       324

13.2.7    STEALTH BIOTHERAPEUTICS INC.         325

13.2.8    ALTEOGEN INC.             326

13.2.9    OCUMENSION THERAPEUTICS 326

13.2.10  INNOVENT        327

13.2.11  SHANGHAI HENLIUS BIOTECH, INC.      327

14          APPENDIX         328

14.1       DISCUSSION GUIDE      328

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             332

14.3       CUSTOMIZATION OPTIONS      334

14.4       RELATED REPORTS       334

14.5       AUTHOR DETAILS         335

LIST OF TABLES

TABLE 1             INCLUSIONS AND EXCLUSIONS 33

TABLE 2             AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

IMPACT ANALYSIS OF MARKET DYNAMICS        57

TABLE 3             AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE), 2021–2023 (USD)              68

TABLE 4             AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER, 2021–2023 (USD)         69

TABLE 5             AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ROLE OF COMPANIES IN ECOSYSTEM             74

TABLE 6             PATENTS FILED, BY DOCUMENT TYPE, 2014–2024          75

TABLE 7             INNOVATIONS AND PATENT REGISTRATIONS, 2019–2023              76

TABLE 8             NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 80

TABLE 9             EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 81

TABLE 10           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 81

TABLE 11           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 82

TABLE 12           MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 83

TABLE 13           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

PORTER’S FIVE FORCES ANALYSIS         83

TABLE 14           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

KEY CONFERENCES AND EVENTS, 2024–2025     86

TABLE 15           BUYING CRITERIA FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS,

BY END USER    88

TABLE 16           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS IN

CLINICAL PIPELINE, PHASE 3    90

TABLE 17           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)        96

TABLE 18           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2023–2029 (MILLION UNITS)     96

TABLE 19           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022–2029 (USD MILLION)              97

TABLE 20           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION)          98

TABLE 21           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION)          98

TABLE 22           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION)          99

TABLE 23           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION)          99

TABLE 24           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022–2029 (USD MILLION)          99

TABLE 25           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION)          100

TABLE 26           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022–2029 (USD MILLION)             101

TABLE 27           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION)          101

TABLE 28           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION)              102

TABLE 29           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION)          102

TABLE 30           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION)          103

TABLE 31           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022–2029 (USD MILLION)              103

TABLE 32           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION)          103

TABLE 33           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022–2029 (USD MILLION)             104

TABLE 34           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION)          105

TABLE 35           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION)              105

TABLE 36           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION)          106

TABLE 37           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION)          106

TABLE 38           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022–2029 (USD MILLION)              106

TABLE 39           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION)          107

TABLE 40           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022–2029 (USD MILLION) 108

TABLE 41           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION)          108

TABLE 42           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION)              109

TABLE 43           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION)          109

TABLE 44           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION)          110

TABLE 45           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022–2029 (USD MILLION)              110

TABLE 46           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION)          110

TABLE 47           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD MILLION)              111

TABLE 48           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)          111

TABLE 49           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)          112

TABLE 50           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)          112

TABLE 51           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)          113

TABLE 52           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD MILLION)          113

TABLE 53           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)          113

TABLE 54           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)      115

TABLE 55           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022–2029 (USD MILLION)      116

TABLE 56           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION)          116

TABLE 57           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION)              117

TABLE 58           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION)          117

TABLE 59           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION)          118

TABLE 60           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022–2029 (USD MILLION)          118

TABLE 61           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION)          118

TABLE 62           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022–2029 (USD MILLION)           119

TABLE 63           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION)          120

TABLE 64           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION)              120

TABLE 65           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION)          121

TABLE 66           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION)          121

TABLE 67           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022–2029 (USD MILLION)          121

TABLE 68           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION)          122

TABLE 69           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022–2029 (USD MILLION)     123

TABLE 70           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION)          123

TABLE 71           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION)              124

TABLE 72           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION)          124

TABLE 73           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION)          125

TABLE 74           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022–2029 (USD MILLION)          125

TABLE 75           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION)          125

TABLE 76           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022–2029 (USD MILLION)              126

TABLE 77           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION)          127

TABLE 78           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION)          127

TABLE 79           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION)          128

TABLE 80           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION)          128

TABLE 81           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022–2029 (USD MILLION)          128

TABLE 82           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION)          129

TABLE 83           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022–2029 (USD MILLION)              130

TABLE 84           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 130

TABLE 85           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION)          131

TABLE 86           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 131

TABLE 87           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 132

TABLE 88           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022–2029 (USD MILLION)          132

TABLE 89           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 132

TABLE 90           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)           134

TABLE 91           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022–2029 (USD MILLION)           135

TABLE 92           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION)          136

TABLE 93           EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION)              136

TABLE 94           ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION)          137

TABLE 95           LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION)          137

TABLE 96           MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022–2029 (USD MILLION)          137

TABLE 97           GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION)          138

TABLE 98           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION)        139

TABLE 99           NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)          139

TABLE 100         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)              140

TABLE 101         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)          140

TABLE 102         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)          141

TABLE 103         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION)          141

TABLE 104         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)          141

TABLE 105         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     143

TABLE 106         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022–2029 (USD MILLION)             144

TABLE 107         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION)          144

TABLE 108         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION)              145

TABLE 109         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION)          145

TABLE 110         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION)          146

TABLE 111         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022–2029 (USD MILLION)              146

TABLE 112         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION)          146

TABLE 113         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022–2029 (USD MILLION) 148

TABLE 114         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION)          148

TABLE 115         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION)              149

TABLE 116         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION)          149

TABLE 117         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION)          150

TABLE 118         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022–2029 (USD MILLION)              150

TABLE 119         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION)          150

TABLE 120         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)         152

TABLE 121         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)           153

TABLE 122         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)          153

TABLE 123         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)              154

TABLE 124         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)          154

TABLE 125         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)          155

TABLE 126         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)          155

TABLE 127         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)          155

TABLE 128         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)          156

TABLE 129         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)          157

TABLE 130         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 157

TABLE 131         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)          158

TABLE 132         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)          158

TABLE 133         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)     158

TABLE 134         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)          159

TABLE 135         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2029 (USD MILLION)              160

TABLE 136         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 160

TABLE 137         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)          161

TABLE 138         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 161

TABLE 139         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 162

TABLE 140         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2029 (USD MILLION)          162

TABLE 141         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 162

TABLE 142         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)            164

TABLE 143         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          166

TABLE 144         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        166

TABLE 145         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              166

TABLE 146         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   167

TABLE 147         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          167

TABLE 148         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          167

TABLE 149         MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN NORTH AMERICA  168

TABLE 150         US HEALTHCARE SPENDING, 2020–2022 (USD MILLION)              169

TABLE 151         US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            170

TABLE 152         US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          170

TABLE 153         US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 171

TABLE 154         US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     171

TABLE 155         US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            171

TABLE 156         CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            172

TABLE 157         CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          173

TABLE 158         CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION)             173

TABLE 159         CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     173

TABLE 160         CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            174

TABLE 161         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            174

TABLE 162         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          175

TABLE 163         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 175

TABLE 164         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     175

TABLE 165         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            176

TABLE 166         EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)            176

TABLE 167         MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN EUROPE    177

TABLE 168         GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            179

TABLE 169         GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          179

TABLE 170         GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 180

TABLE 171         GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     180

TABLE 172         GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            180

TABLE 173         UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            181

TABLE 174         UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          182

TABLE 175         UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 182

TABLE 176         UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     182

TABLE 177         UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            183

TABLE 178         FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            184

TABLE 179         FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          184

TABLE 180         FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 185

TABLE 181         FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     185

TABLE 182         FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            185

TABLE 183         ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            187

TABLE 184         ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          187

TABLE 185         ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 188

TABLE 186         ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)  188

TABLE 187         ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            188

TABLE 188         SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY PRODUCT, 2022–2029 (USD MILLION)        190

TABLE 189         SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY MOLECULE, 2022–2029 (USD MILLION)      190

TABLE 190         SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)           191

TABLE 191         SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)  191

TABLE 192         SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022–2029 (USD MILLION)         191

TABLE 193         NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          192

TABLE 194         NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        193

TABLE 195         NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              193

TABLE 196         NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   193

TABLE 197         NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          194

TABLE 198         REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          194

TABLE 199         REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        195

TABLE 200         REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              195

TABLE 201         REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   195

TABLE 202         REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          196

TABLE 203         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            198

TABLE 204         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          198

TABLE 205         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 199

TABLE 206         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     199

TABLE 207         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            199

TABLE 208         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)            200

TABLE 209         MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN ASIA PACIFIC         201

TABLE 210         CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            202

TABLE 211         CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          203

TABLE 212         CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 203

TABLE 213         CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)  203

TABLE 214         CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            204

TABLE 215         JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            205

TABLE 216         JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          205

TABLE 217         JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 205

TABLE 218         JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)  206

TABLE 219         JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            206

TABLE 220         INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            207

TABLE 221         INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          207

TABLE 222         INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 208

TABLE 223         INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)  208

TABLE 224         INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            208

TABLE 225         AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            210

TABLE 226         AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          210

TABLE 227         AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 211

TABLE 228         AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     211

TABLE 229         AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            211

TABLE 230         SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          212

TABLE 231         SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        213

TABLE 232         SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              213

TABLE 233         SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   213

TABLE 234         SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          214

TABLE 235         REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          215

TABLE 236         REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)          215

TABLE 237         REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)          215

TABLE 238         REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)          216

TABLE 239         REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          216

TABLE 240         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          217

TABLE 241         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        217

TABLE 242         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              217

TABLE 243         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   218

TABLE 244         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET,

BY END USER, 2022–2029 (USD MILLION)            218

TABLE 245         LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          218

TABLE 246         MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN LATIN AMERICA    220

TABLE 247         BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            221

TABLE 248         BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          221

TABLE 249         BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 222

TABLE 250         BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)  222

TABLE 251         BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            222

TABLE 252         MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            223

TABLE 253         MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          224

TABLE 254         MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 224

TABLE 255         MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     224

TABLE 256         MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            225

TABLE 257         REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          226

TABLE 258         REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)          226

TABLE 259         REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)          226

TABLE 260         REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)          227

TABLE 261         REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          227

TABLE 262         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          228

TABLE 263         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        228

TABLE 264         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              228

TABLE 265         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   229

TABLE 266         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          229

TABLE 267         MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 229

TABLE 268         MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN MIDDLE EAST        230

TABLE 269         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          231

TABLE 270         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        231

TABLE 271         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              232

TABLE 272         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   232

TABLE 273         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          232

TABLE 274         GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          233

TABLE 275         SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          234

TABLE 276         SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)        234

TABLE 277         SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)              234

TABLE 278         SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)   235

TABLE 279         SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          235

TABLE 280         UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            236

TABLE 281         UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          236

TABLE 282         UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 237

TABLE 283         UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2022–2029 (USD MILLION)     237

TABLE 284         UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            237

TABLE 285         OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          238

TABLE 286         OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)          239

TABLE 287         OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)          239

TABLE 288         OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)          239

TABLE 289         OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          240

TABLE 290         REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          241

TABLE 291         REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION)          241

TABLE 292         REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION)          242

TABLE 293         REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)          242

TABLE 294         REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION)          242

TABLE 295         AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            243

TABLE 296         AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY MOLECULE, 2022–2029 (USD MILLION)          244

TABLE 297         AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY APPROVAL TYPE, 2022–2029 (USD MILLION) 244

TABLE 298         AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION)  244

TABLE 299         AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY END USER, 2022–2029 (USD MILLION)            245

TABLE 300         MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN AFRICA      246

TABLE 301         OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET      248

TABLE 302         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

DEGREE OF COMPETITION       252

TABLE 303         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

MOLECULE FOOTPRINT            257

TABLE 304         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

APPROVAL TYPE FOOTPRINT   258

TABLE 305         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

TYPE OF AMD FOOTPRINT        259

TABLE 306         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

REGION FOOTPRINT    260

TABLE 307         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

DETAILED LIST OF KEY STARTUPS/SMES           263

TABLE 308         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES         264

TABLE 309         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024       268

TABLE 310         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

DEALS, JANUARY 2021– AUGUST 2024    270

TABLE 311         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: EXPANSIONS, JANUARY 2021–AUGUST 2024    271

TABLE 312         F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW  272

TABLE 313         F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED   273

TABLE 314         F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     274

TABLE 315         REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW              276

TABLE 316         REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED              277

TABLE 317         REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024      277

TABLE 318         NOVARTIS AG: COMPANY OVERVIEW   279

TABLE 319         NOVARTIS AG: PRODUCTS OFFERED    281

TABLE 320         NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024        281

TABLE 321         NOVARTIS AG: DEALS, JANUARY 2021–AUGUST 2024      282

TABLE 322         BAYER AG: COMPANY OVERVIEW          283

TABLE 323         BAYER AG: PRODUCTS OFFERED           284

TABLE 324         BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024        285

TABLE 325         APELLIS PHARMACEUTICALS: COMPANY OVERVIEW    287

TABLE 326         APELLIS PHARMACEUTICALS: PRODUCTS OFFERED     287

TABLE 327         APELLIS PHARMACEUTICALS: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     288

TABLE 328         APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021–AUGUST 2024      288

TABLE 329         ASTELLAS PHARMA INC.: COMPANY OVERVIEW             290

TABLE 330         ASTELLAS PHARMA INC.: PRODUCTS OFFERED 291

TABLE 331         ASTELLAS PHARMA INC.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     292

TABLE 332         ASTELLAS PHARMA INC.: DEALS, JANUARY 2021–AUGUST 2024              292

TABLE 333         STADA ARZNEIMITTEL AG: COMPANY OVERVIEW         293

TABLE 334         STADA ARZNEIMITTEL AG: PRODUCTS OFFERED          294

TABLE 335         STADA ARZNEIMITTEL AG: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     295

TABLE 336         STADA ARZNEIMITTEL AG: DEALS, JANUARY 2021–AUGUST 2024      296

TABLE 337         BIOGEN: COMPANY OVERVIEW 297

TABLE 338         BIOGEN: PRODUCTS OFFERED 298

TABLE 339         BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024    299

TABLE 340         FORMYCON AG: COMPANY OVERVIEW 301

TABLE 341         FORMYCON AG: PRODUCTS OFFERED 302

TABLE 342         FORMYCON AG: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     303

TABLE 343         FORMYCON AG: DEALS, JANUARY 2021–AUGUST 2024   304

TABLE 344         COHERUS BIOSCIENCES: COMPANY OVERVIEW             305

TABLE 345         COHERUS BIOSCIENCES: PRODUCTS OFFERED 305

TABLE 346         COHERUS BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     306

TABLE 347         COHERUS BIOSCIENCES: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024        306

TABLE 348         BIOCON: COMPANY OVERVIEW             307

TABLE 349         BIOCON: PRODUCTS OFFERED 308

TABLE 350         BIOCON: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024    309

TABLE 351         BIOCON: DEALS, JANUARY 2021–AUGUST 2024  309

TABLE 352         OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW              310

TABLE 353         OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED 310

TABLE 354         OUTLOOK THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     311

TABLE 355         OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2021–AUGUST 2024    311

TABLE 356         TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW        312

TABLE 357         TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED          313

TABLE 358         TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–AUGUST 2024             314

TABLE 359         TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021–AUGUST 2024        314

TABLE 360         INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW              315

TABLE 361         INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED              315

TABLE 362         SANDOZ GROUP AG: COMPANY OVERVIEW      316

TABLE 363         SANDOZ GROUP AG: PRODUCTS OFFERED       317

TABLE 364         SANDOZ GROUP AG: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–AUGUST 2024     318

TABLE 365         SANDOZ GROUP AG: DEALS, JANUARY 2021–AUGUST 2024              318

TABLE 366         SANDOZ GROUP AG: EXPANSIONS, JANUARY 2021–AUGUST 2024      318

TABLE 367         CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW  319

TABLE 368         CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED   319

TABLE 369         OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW    320

TABLE 370         OPTHEA LIMITED: COMPANY OVERVIEW          321

TABLE 371         KODIAK SCIENCES INC.: COMPANY OVERVIEW 322

TABLE 372         BIO-THERA: COMPANY OVERVIEW        323

TABLE 373         AMGEN INC.: COMPANY OVERVIEW      323

TABLE 374         ALVOTECH: COMPANY OVERVIEW        324

TABLE 375         STEALTH BIOTHERAPEUTICS INC.: COMPANY OVERVIEW              325

TABLE 376         ALTEOGEN INC.: COMPANY OVERVIEW             326

TABLE 377         OCUMENSION THERAPEUTICS: COMPANY OVERVIEW 326

TABLE 378         INNOVENT: COMPANY OVERVIEW        327

TABLE 379         SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW              327

LIST OF FIGURES

FIGURE 1           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION         34

FIGURE 2           RESEARCH DESIGN       37

FIGURE 3           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

BREAKDOWN OF PRIMARY INTERVIEWS            39

FIGURE 4           MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023              40

FIGURE 5           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

REVENUE SHARE ANALYSIS, 2023           41

FIGURE 6           ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: COMPANY REVENUE SHARE ANALYSIS, 2023      41

FIGURE 7           MARKET VALIDATION FROM PRIMARY EXPERTS           42

FIGURE 8           BOTTOM-UP APPROACH           43

FIGURE 9           AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

CAGR PROJECTIONS, 2024–2029 44

FIGURE 10         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

GROWTH ANALYSIS OF MARKET DYNAMICS     45

FIGURE 11         DATA TRIANGULATION             46

FIGURE 12         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)   48

FIGURE 13         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION) 49

FIGURE 14         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION) 49

FIGURE 15         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY TYPE OF APPROVAL, 2024 VS. 2029 (USD MILLION)   50

FIGURE 16         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)   51

FIGURE 17         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,

BY REGION, 2024–2029  52

FIGURE 18         GROWING GERIATRIC POPULATION AND CHANGING LIFESTYLES TO DRIVE MARKET             53

FIGURE 19         BIOLOGICS SEGMENT AND US DOMINATED NORTH AMERICAN MARKET IN 2023      54

FIGURE 20         WET AMD SEGMENT TO LEAD MARKET BY 2029             54

FIGURE 21         HOSPITALS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023  55

FIGURE 22         NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD       55

FIGURE 23         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    56

FIGURE 24         REVENUE SHIFT & NEW POCKETS FOR AGE-RELATED MACULAR

DEGENERATION THERAPY PROVIDERS 67

FIGURE 25         AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2021–2023 (USD)   69

FIGURE 26         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

VALUE CHAIN ANALYSIS            70

FIGURE 27         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

SUPPLY CHAIN ANALYSIS          72

FIGURE 28         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

ECOSYSTEM ANALYSIS 73

FIGURE 29         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

PATENT ANALYSIS, 2014–2024   76

FIGURE 30         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

PORTER’S FIVE FORCES ANALYSIS         84

FIGURE 31         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AGE-RELATED

MACULAR DEGENERATION (AMD) DRUGS        87

FIGURE 32         KEY BUYING CRITERIA, BY END USER    87

FIGURE 33         IMPACT OF ARTIFICIAL INTELLIGENCE ON AGE-RELATED MACULAR

DEGENERATION (AMD) DRUGS MARKET           93

FIGURE 34         NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD)

DRUGS MARKET SNAPSHOT     165

FIGURE 35         ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD)

DRUGS MARKET SNAPSHOT     197

FIGURE 36         REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION)          250

FIGURE 37         MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023          251

FIGURE 38         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023           255

FIGURE 39         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

COMPANY FOOTPRINT 256

FIGURE 40         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:

COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023        262

FIGURE 41         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS             265

FIGURE 42         EV/EBITDA OF KEY VENDORS   266

FIGURE 43         AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BRAND/PRODUCT COMPARISON       267

FIGURE 44         F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)              273

FIGURE 45         REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2023)   276

FIGURE 46         NOVARTIS AG: COMPANY SNAPSHOT (2023)     280

FIGURE 47         BAYER AG: COMPANY SNAPSHOT (2023)            284

FIGURE 48         ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023) 291

FIGURE 49         STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2023)              294

FIGURE 50         BIOGEN: COMPANY SNAPSHOT (2023)  298

FIGURE 51         FORMYCON AG: COMPANY SNAPSHOT (2023)   302

FIGURE 52         BIOCON: COMPANY SNAPSHOT (2023) 308

FIGURE 53         TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)          313

FIGURE 54         SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)        317

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧